Scientific Name: Retatrutide
Manufacturer: Zhengzhou Pharmaceutical (ZPHC)
Form: 5 lyophilized vials × 8 mg (total 40 mg)
Category: Metabolic/weight‑management research compound
Mechanism: Retatrutide is a dual incretin agonist (GLP‑1 and GIP) that enhances appetite suppression, improves insulin sensitivity, and accelerates fat reduction.
⚗️ Storage & Handling
-
Store refrigerated at 2–8 °C (35–46 °F)
-
Protect from light; keep vials sealed until reconstitution
-
Maintain cold‑chain integrity during shipping
-
For research use only — not approved for human consumption outside supervised protocols
Parameter Standard Range Notes Total content 40 mg 5 vials × 8 mg Administration Subcutaneous injection Abdomen, thigh, or upper arm Frequency Weekly Long half‑life supports once‑weekly dosing Timing Morning (fasted) Enhances appetite suppression and metabolic response Research focus Appetite suppression, insulin sensitivity, fat loss Dual incretin agonist
